HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Givaudan

This article was originally published in The Rose Sheet

Executive Summary

Swiss fragrance and flavors company recently introduced Cosmone, a "novel" fragrance ingredient described as an "intensely rich, powerful and elegant musk," firm announces in first quarter earnings release. Slow retail sales during the 2008 holiday season in North America and Europe led to destocking of fine fragrances in the quarter, resulting in a decline in total fragrance sales of 10.4 percent (5.4 percent in local currencies) to $382.3 million (CHF1=$.87), company reports. Lack of consumer confidence and reduced travel is likely to impact fine fragrance sales throughout 2009, firm notes. Net sales for the period declined 7.3 percent (2.6 percent in local currencies) to $850.7 million, Givaudan reports. Despite first quarter performance, Givaudan expects its total fragrance and flavors businesses will outgrow the underlying market

You may also be interested in...



Lumakras A Big Focus For Amgen; More Data Coming Soon

Amgen reported 5% year-over-year revenue growth to $6.5bn in the second quarter, up 11% from Q1. It did not break out Lumakras sales but detailed upcoming data that may support future indications.

Medicare Coverage With Evidence Development Mandate Expires After Four Years Under Senate Bill

As CMS brings public attention to process with its national coverage analysis for Alzheimer’s drugs, legislation aims to encourage quick recommendations – and strengthen collaboration with FDA.

Istodax’s Lymphoma Accelerated Approval Indication Falls Victim To Failed Confirmatory Trial

BMS’ histone deacetylase inhibitor is the first oncology drug outside the PD-1/L1 class to lose an indication under US FDA’s recent review of ‘dangling’ accelerated approvals. Claim for second-line peripheral T-cell lymphoma was withdrawn because first-line study failed to meet its progression-free survival endpoint.

UsernamePublicRestriction

Register

RS016095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel